Effects of L-DOPA-therapy on dopamine D2 receptor mRNA expression in the srtiatum of MPTP-intoxicated parkinsonian monkeys

Molecular Brain Research

Volumn 42, Issue 1, 1996, Pages 149-155

  Herrero, M T ^a   Augood, S J ^b   Asensi, H ^a   Hirsch, E G ^c   Agid, Y ^c   Obeso, J A ^d   Emson, P C ^b  

^a UNIVERSITY OF MURCIA   (Spain)

^b BABRAHAM INSTITUTE   (United Kingdom)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^d HOSPITAL QUIRÓN   (Spain)

Author keywords

Dopamine D2 receptor; Dyskinesia; Hybridization, in situ; L DOPA; Monkey; MPTP; Parkinson's disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ANTIPARKINSON AGENT; DOPAMINE 2 RECEPTOR; LEVODOPA; MESSENGER RNA;

ANIMAL EXPERIMENT; ARTICLE; CAUDATE NUCLEUS; CONTROLLED STUDY; CORPUS STRIATUM; DYSKINESIA; IN SITU HYBRIDIZATION; MONKEY; NONHUMAN; PARKINSONISM; PRIORITY JOURNAL; PUTAMEN;

ANIMALIA; MACACA FASCICULARIS; PARKINSONIA;

EID: 2042517483     PISSN: 0169328X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-328X(96)00157-X     Document Type: Article

References (65)

1. [1] Albin, R.L., Young, A.B. and Penney, J.B., The functional neuroanatomy of the basal ganglia disorders, Trends Neurosci., 12 (1989) 366-375.
2. [2] Alexander, G.M., Schwartzman, R.J., Grothusen, J.R., Brainard, L. and Gordon, S.W., Changes in brain dopamine receptors in MPTP parkinsonian monkeys following L-DOPA treatment, Brain Res., 625 (1993) 276-282.
3. [3] Angulo, J.A. and McEwen, B.S., Molecular aspects of neuropeptide regulation and function in the corpus striatum and nucleus-accumbens, Brain Res. Rev., 19 (1994) 1-28.
4. [4] Augood, S.J., Emson, P.C., Mitchell, I.J., Boyce, S., Clarke, C.E. and Crossman, A.R., Cellular localization of enkephalin gene expression in MPTP-treated cynomolgus monkeys, Mol. Brain Res., 6 (1989) 85-92.
5. [5] Augood, S.J., Westmore, K., Faull, R.L.M. and Emson, P.C., Neuroleptics and striatal neuropeptide gene expression. In P.C. Emson and G.W. Arbuthnott (Eds.), Progress in Brain Research, Vol. 99, Elsevier, Amsterdam, 1993, pp. 181-199.
6. 2 receptors, Nature, 377 (1995) 424-428.
7. [7] Bédard, P.J., Gomez-Mancilla, B., Blanchet, P., Gagnon, C., Falardeau, P. and Dipaolo, T., Role of selective D1 and D2 agonists in inducing dyskinesias in drug-naive MPTP monkeys, Adv. Neurol., 60 (1993) 113-118.
8. [8] Bédard, P.J., Gomez-Mancilla, B., Blanchet, P., Grondin, R. and Dipaolo, T., Dopamine-receptor families and the treatment of Parkinson's disease. Clin. Pharmacol., 18 (1995) 178-187.
9. [9] Bennett, J.P., Landow, E.R., Dietrich, S. and Schuh, L.A., Suppression of dyskinesias in advanced Parkinson's disease - moderate daily clozapine doses provide long-term dyskinesia reduction, Movement Disorders, 9 (1994) 409-414.
10. [10] Bergman, H., Wichmann, T. and DeLong, M.R., Reversal of experimental parkinsonism by lesions of the subthalamic nucleus, Science, 249 (1990) 1436-1438.
11. 2 receptor mRNA in response to haloperidol treatment: a quantitative in situ hybridization study, Neuroscience, 45 (1991) 117-126.
12. [12] Blanchet, P.J., Gomez-Mancilla, B., Dipaolo, T. and Bédard, P.J., Is striatal dopaminergic receptor imbalance responsible for levodopa-induced dyskinesias, Fund. Clin. Pharmacol., 9 (1995) 434-442.
13. [13] Boyce, S., Rupniak, N.M.J., Stevenson, M.J. and Iversen, S.D., Differential effects of D1 and D2 agonists in MPTP-treated primates: functional implications for Parkinson's disease, Neurology, 40 (1990) 927-933.
14. [14] Braak, H. and Braak, E., Neuronal types in the striatum of man, Cell Tissue Res., 227 (1982) 319-342.
15. [15] Chiueh, C.C., Markey, S.P., Burns, R.S., Johannessen, J.N., Jacobowitz, D.M. and Kopm, O.J., Selective neurotoxic effects of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in subhuman primates and man: a new animal model of Parkinson's disease, Psychopharm. Bull., 20 (1984) 548-553.
16. [16] Corini, H., Schumacher, M., Angulo, J.A. and McEwen, B.S., Increase in striatal dopamine D2 receptor mRNA after lesions of haloperidol treatment, Eur. J. Pharmacol., 186 (1990) 369-371.
17. [17] Dawson, V.L., Dawson, T.M., Filloux, F.M. and Warmsley, J.K., Evidence for dopamine D-2 receptors on cholinergic interneurons in the rat caudate-putamen, Life Sci., (1988) 1933-1939.
18. [18] Di Chiara, G., Morelli, M and Consolo, S., Modulatory functions of neurotransmitters in the striatum: ACh/dopamine/NMDA interactions, Trends Neurosci., 17 (1994) 228-233.
19. 2 receptors and neuropeptides in striatonigral and striatopallidal neurons of rats with neuroleptic-induced dyskinesias, Synapse, 18 (1994) 178-189.
20. 2 receptor interactions in the MPTP-treated marmoset, Neurosci. Lett., 142 (1992) 1-4.
21. [21] Filion, M. and Tremblay, L., Abnormal spontaneous activity of globus pallidus neurones in monkeys with MPTP-induced parkinsonism, Brain Res., 547 (1991) 142-151.
22. 2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons, Science, 250 (1990) 1429-1432.
23. [23] Gomez-Mancilla, B. and Bédard, P.J., Effect of nondopaminergic drugs on L-DOPA-induced dyskinesias in MPTP-treated monkeys, Clin. Neuropharmacol., 16 (1993) 418-427.
24. [24] Graham, W.C., Clarke, C.E., Boyce, S., Sambrook, M.A., Cross-man, A.R. and Woodruff, G.N., Autoradiographic studies in animal models of hemi-parkinsonian reveal dopamine D2 but not D1 receptor supersensitivity. II. Unilateral intra-carotid infusion of MPTP in the monkey (Macaca fascicularis), Brain Res., 514 (1990) 103-110.
25. [25] Graham, W.C., Sambrook, M.A. and Crossman, A.R., Differential effect of chronic dopaminergic treatment on dopamine D1 and D2 receptors in the monkey brain in MPTP-induced parkinsonism, Brain Res., 602 (1993) 290-303.
26. 2 dopamine receptor, Proc. Natl. Acad. Sci. USA, 86 (1989) 9762-9766.
27. 2 dopamine receptors in Parkinson's disease striatum, J. Neural Transm., 64 (1985) 93-103.
28. 2 receptor, preproenkephalin A and preprotachykinin gene expression in human control and schizophrenic caudate nucleus: a quantitative cellular in situ hybridization study, Mol. Brain Res., 33 (1995) 333-342.
29. [29] Hassani, O.K., Mouroux, M. and Féger, J., Increased subthalamic neuronal activity after nigral dopaminergic lesion independent of disinhibition via the globus pallidus, Neuroscience, 72 (1996) 105-115.
30. [30] Herrero M.-T., Hirsch, E.C., Kastner, A., Luquin, M.R., Laguna, J., Javoy-Agid, F., Obeso, J.A. and Agid, Y., Does neuromelanin contribute to the vulnerability of catecholaminergic neurones in monkeys intoxicated with MPTP?, Neuroscience, 56 (1993) 499-511.
31. [31] Herrero, M.-T., Augood, S.J., Hirsch, E.G., Javoy-Agid, F., Luquin, M.R. Agid, Y., Obeso, J.A. and Emson, P.C., Effects of L-DOPA on preproenkephalin and preprotachykinin gene expression in the MPTP-treated monkey striatum, Neuroscience, 68 (1995) 1189-1198.
32. [32] Herrero, M.-T., Levy, R, Ruberg, M., Javoy-Agid, F., Agid, Y., Obeso, J.A. and Hirsch, E.C., GAD mRNA expression in the internal and external segment of the globus pallidus in parkinsonism. In L. Battistin et al. (Eds.), Advances in Neurology 69: Parkinson's Disease, Lippincott Raven, Philadelphia, 1996, pp. 209-216.
33. [33] Hersch, S.M., Ciliax, B.J., Gutekunst, C.-A., Rees, H.D., Heilman, C.J. Yung, K.K.L., Bolam, J.P., Ince, E., Yi, H. and Levey, A.I., Electron microscopic analysis of D1 and D2 dopamine receptor proteins in the dorsal striatum and their synaptic relationships with corticostriatal afferents, J. Neurosci., 15 (1995) 5222-5237.
34. [34] Huntley, G.W., Morrison, J.H., Prikhozhan, A. and Sealfon, S.C., Localization of multiple dopamine receptor subtype mRNAs in human and monkey motor cortex and striatum, Mol. Brain Res., 15 (1992) 181-188.
35. [35] Izzo, P.N. and Bolam, J.P., Cholinergic synaptic input to different parts of spiny striatonigral neurons in the rat, J. Comp. Neurol., 269 (1988) 219-234.
36. [36] Javoy-Agid, F., Ruberg, M., Hirsch, E., Cash, R., Raisman, R., Taquet, H., Epelbaum, J., Scatton, B., Duyckaerts, C. and Agid, Y., Recent progress in the neurochemistry of Parkinson's disease. In S. Fahn et al. (Eds.), Recent Developments in Parkinson's Disease, Raven Press, New York, 1986, pp. 67-83.
37. [37] Jellinger, K., Pathology of Parkinsonism. In S. Fahn et al. (Eds.), Recent Developments in Parkinson's Disease, Raven Press, New York, 1986, pp. 33-66.
38. [38] Jolkkonen, J., Jenner, P. and Marsden, C.D., L-DOPA reverses altered gene expression in the caudate-putamen of common marmosets treted with MPTP, Mol. Brain Res., 32 (1995) 297-307.
39. [39] Kawaguchi, Y., Wilson, C.J., Augood, S.J. and Emson, P.C., Striatal interneurones: chemical, physiological and morphological characterization, Trends Neurosci., 18 (1995) 527-535.
40. 3H]raclopride, Neurosci. Lett., 66 (1986) 85-90.
41. [41] Kostrzewa, R.M., Dopamine receptor supersensitivity, Neurosci. Biobehav. Rev., 19 (1995) 1-17.
42. [42] Laitinen, L.V., Bergenheim, A.T. and Hariz, M.I., Leskell's posteroventral pallidotomy in the treatment of Parkinson's disease, J. Neurosurg., 76 (1992) 53-61.
43. [43] Langston, J.W., Ballard, P., Tetrud, J.W. and Irwin, I., Chronic parkinsonism in humans due to a product of meperidine-analog synthesis, Science, 219 (1983) 979-980.
44. [44] Lehmann, J. and Langer, S.Z., The striatal cholinergic interneuron: synaptic target of dopaminergic terminals? Neuroscience, 10 (1983) 1105-1120.
45. [45] Le Moine, C., Normand, E., Guitteny, A.F., Fouque, B., Teoule, R. and Bloch, B., Dopamine receptor gene expression by enkephalin neurons in rat forebrain, Proc. Natl. Acad. Sci. USA, 87 (1990) 230-234.
46. 9 dopamine receptor gene expression by cholinergic neurons in the rat striatum, Neurosci Lett., 117 (1990) 248-252.
47. 67 mRNA, Eur. J. Neurosci., 7 (1995) 1199-1209.
48. [48] Levy, R., Hazrati, L.N., Herrero, M.T., Vila, M., Hassani, O.K., Mouroux, M., Guridi, J., Ruberg, M., Agid, Y., Feger, J., Obeso, J.A., Parent, A. and Hirsch, E.C., Re-evaluation of the functional anatomy of the basal ganglia in normal and parkinsonian states, Neuroscience, (1996) (in press).
49. [49] Lozano, A., Hutchison, W., Kiss, Z., Tasker, R., Davis, K. and Dostrovsky, J., Methods for microelectrode-guided posteroventral pallidotomy, J. Neurosurg., 84 (1996) 194-202.
50. [50] Lucas, L.R. and Harlan, R.E., Cholinergic regulation of tachykinin-and enkephalin-gene expression in the rat striatum, Mol. Brain Res., 30 (1995) 181-195.
51. [51] Luquin, M.R., Laguna, J. and Obeso, J.A., Selective D2-receptor stimulation induces dyskinesia in parkinsonian monkeys, Ann. Neurol., 31 (1992) 551-554.
52. [52] Luquin, M.R., Scipioni, O., Vaamonde, J., Gershanik, O. and Obeso, J.A., Levodopa-induced dyskinesias in Parkinson's disease - clinical and pharmacological classification, Movement Disorders, 7 (1992) 117-124.
53. 2 receptor binding in the rat brain and pituitary: an in situ hydridization-receptor autoradiographic analysis. J. Neurosci., 10 (1990) 2587-2600.
54. [54] Mitchell, I.J., Clarke, C.E., Boyce, S., Robertson, R.G., Peggs, D., Sambrook, M.A. and Crossman, A.R., Neural mechanisms underlying parkinsonian symptoms based upon regional uptake of 2-deoxyglucose in monkeys exposed to 1-methyl-4-phenyl-1,2,3,6-tetra-hydropyridine, Neuroscience, 32 (1989) 213-226.
55. [55] Nutt, G.J., Levodopa-induced dyskinesia: review, observations, and speculations, Neurology, 40 (1990) 340-345.
56. [56] Pierot, L., Desnos, C., Blin, J., Raisman, R., Scherman, D., Javoy-Agid, F., Ruberg, M. and Agid, Y., D1 and D2-type dopamine receptors in patients with parkinson's disease and progressive supranuclear palsy, J. Neurol. Sci., 86 (1988) 291-306.
57. [57] Pollack, A.E. and Wooten, G.F., D2 dopaminergic regulation of striatal preproenkephalin mRNA levels is mediated at least in part through cholinergic interneurons, Mol. Brain Res., 13 (1992) 35-41.
58. 5 receptor mRNAs in monkey striatum. Brain Res., 616 (1993) 242-250.
59. [59] Rinne, J.O., Laihinen, A., Lönnberg, P., Marjamäki, P. and Rinne, U.K., A post-mortem study on striatal dopamine receptors in Parkinson's disease, Brain Res., 556 (1991) 117-122.
60. [60] Starr, M.S., Glutamate/dopamine D1/D2 balance in the basal ganglia and its relevance to Parkinson's disease, Synapse, 19 (1995) 264-293.
61. [61] Strada, O., Vyas, S., Hirsch, E.G., Ruberg, M., Brice, A., Agid, Y. and Javoy-Agid, F., Decreased choline acetyltransferase mRNA expression in the nucleus basalis of Meynert in Alzheimer's disease. An in situ hybridization study, Proc. Natl. Acad. Sci. USA, 89 (1992) 9549-9553.
62. [62] Surmeier, D.J., Reiner, A., Levine, M.S. and Ariano, M.A., Are neostriatal dopamine receptors co-localized? Trends Neurosci., 16 (1993) 299-305.
63. [63] Thomas, K.L., Rose, S., Jenner, P. and Marsden, C.D., Dissociation of the striatal D2 dopamine receptor from adenylyl cyclase following 6-hydroxydopamine-induced denervation, Biochem. Pharmacol., 44 (1992) 73-82.
64. [64] Young, W.S., Bonner, T.I. and Brann, M.R., Mesencephalic dopamine neurones regulate the expression of neuropeptide mRNAs in the rat forebrain, Proc. Natl. Acad. Sci. USA, 83 (1986) 9827-9831.
65. [65] Yung, K.K.L., Bolam, J.P., Smith, A.D., Hersch, S.M., Ciliax, B.J. and Levey, A.I., lmmunocytochemical localization of D1 and D2 dopamine receptors in the basal ganglia of the rat: light and electron microscopy. Neuroscience, 65 (1995) 709-730.